The North America Body Fluid Collection And Diagnostics Market would witness market growth of 6.5% CAGR during the forecast period (2022-2028).
The body fluid of humans contains saliva, blood, excreta, cerebrospinal fluid, and fluids of tissues are considered inviting sources for clinical biomarkers, specifically in chronic diseases which extremely impact human life. The examination of human body fluid allows for diagnosing diseases and tracking disease causes. It enables the forecast of prognosis and tracking of disease growth with affordability, less invasiveness, and quick sample collection & analysis.
Moreover, the structure of molecular expression level in the body fluid can assist in the revelation of modification of psychological position and cellular in the affected tissue. Thus, body fluid analysis is the most valuable process for the identification, tracking, management, and pre-response analysis of chronic disease and for reveling the possible pathogens of chronic disease.
By the body fluid analysis process, which is considered as a most favorable approaches in practice, one can identify chronic diseases like diabetes, hypertension, cancer, and glaucoma. This can help on building a more inclusive approach to the mechanism of pathology and physiology in chronic diseases, which could have a crucial role in offering early proof, more productive care, and greater patient results.
As per the Canadian Cancer Statistic by Canadian government, throughout the life period of a Canadian citizen, 43% of Canadian women and 45% of Canadian men have cancer. As the population of Canada will rise and become older, there will be increasing cases of new cancer patients. Cancer is the major cause of many deaths in Canada. Apart from the present improvement in cancer management and research, rising partiality care of cancer patients has been seen, especially with those who are socio-economically disadvantaged groups and under-served society.
The government of Canada is supporting those organizations who are helping out to fight against this disease. The Canadian government recently introduced a plan to offer $250 million dollars for five years to expand the work of these organizations that are fighting against cancer. With the rising number of cancer patients in Canada, there will be great investment opportunities for the major players in the regional market.
The US market dominated the North America Body Fluid Collection And Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $12,613.9 million by 2028. The Canada market is poised to grow at a CAGR of 8.9% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 7.9% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Consumables, Instruments and Tests/Services. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescence in situ hybridization (FISH) and Others. Based on Sample Type, the market is segmented into Blood, Urine, Saliva and Cerebrospinal Fluid. Based on Application, the market is segmented into Diagnostics & Monitoring, Therapeutic Decision Making and Prognostics & Screening. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Body Fluid Collection And Diagnostics Market is Estimated to reach $42.2 Billion by 2028, at a CAGR of 6.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Biocept, Inc., MDxHealth SA, and Guardant Health, Inc.
By Product
By Technology
By Sample Type
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
